Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy
- PMID: 35654062
- DOI: 10.1016/S1470-2045(22)00258-3
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy
Conflict of interest statement
GM reports personal fees from Merck and Roche; grants and personal fees from Bristol Myers Squibb and Novartis; personal fees and stock options from 4C Biomed; and stock options from Nucleai, Biond Biologics, and Ella Therapeutics, outside the submitted work. TM reports personal fees from TyrNovo, outside of the submitted work. All other authors declare no competing interests.
Comment in
-
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy - Authors' reply.Lancet Oncol. 2022 Jun;23(6):e246. doi: 10.1016/S1470-2045(22)00299-6. Lancet Oncol. 2022. PMID: 35654063 No abstract available.
Comment on
-
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.Lancet Oncol. 2022 May;23(5):659-670. doi: 10.1016/S1470-2045(22)00197-8. Epub 2022 Apr 12. Lancet Oncol. 2022. PMID: 35427471 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical